Thomas J Sharpe

US Patent:

6552066, Apr 22, 2003

Filed:

Mar 10, 1998

Appl. No.:

09/038187

Inventors:

Thomas R. Sharpe - Wilmington DE 19803
George W. Vasios - Brookline MA 02146
R. Nelson Campbell - Bethesda MD 20814

International Classification:

A61K 3140

US Classification:

514419, 514520, 514523

Abstract:

Disclosed is a method of treating an individual or animal with osteoarthritis. The method comprises administering to the individual or animal a therapeutically effective amount of a protein tyrosine kinase inhibitor.

US Patent:

20030060515, Mar 27, 2003

Filed:

Sep 23, 2002

Appl. No.:

10/252999

Inventors:

Thomas Sharpe - Wilmington DE, US
George Vasios - Brookline MA, US
R. Campbell - Bethesda MD, US

Assignee:

The Osteoarthritis Sciences, Inc. Liquidating Trust - Boston MA

International Classification:

A61K031/045
A61K031/075

US Classification:

514/730000, 514/720000

Abstract:

Disclosed is a method of treating an individual or animal with osteoarthritis. The method comprises administering to the individual or animal a therapeutically effective amount of a protein tyrosine kinase inhibitor.

US Patent:

41827694, Jan 8, 1980

Filed:

Jan 5, 1978

Appl. No.:

5/865831

Inventors:

Saul C. Cherkofsky - Wilmington DE
Thomas R. Sharpe - Fort Salonga NY

Assignee:

E. I. Du Pont de Nemours and Company - Wilmington DE

International Classification:

C07D23384
C07D40504
A61K 31415

US Classification:

424273R

Abstract:

Anti-inflammatory 1-substituted-4,5-diaryl-2-(substituted-thio) imidazoles and their corresponding sulfoxides and sulfones useful for treating arthritis and related diseases.

US Patent:

41984218, Apr 15, 1980

Filed:

Nov 30, 1978

Appl. No.:

5/965075

Inventors:

Saul C. Cherkofsky - Wilmington DE
Thomas R. Sharpe - Fort Salonga NY

Assignee:

E. I. Du Pont de Nemours and Company - Wilmington DE

International Classification:

A61K 31415
C07D49104

US Classification:

424273R

Abstract:

Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles, such as 10-fluoro-2-[(1,1,2,2-tetrafluoroethyl)sulfonyl]-1H-dibenzo[2,3:6,7]oxepin o[4,5-d]imidazole, useful for treating arthritis and related diseases.

US Patent:

41906667, Feb 26, 1980

Filed:

Feb 10, 1978

Appl. No.:

5/876864

Inventors:

Saul C. Cherkofsky - Wilmington DE
Thomas R. Sharpe - Fort Salonga NY

Assignee:

E. I. Du Pont de Nemours and Company - Wilmington DE

International Classification:

A61K 31415
C07D23384
C07D23386

US Classification:

424274

Abstract:

Anti-inflammatory 4,5-diaryl-2-(substituted-thio)imidazols and their corresponding sulfoxides and sulfones useful for treating arthritis and related diseases.

US Patent:

42151350, Jul 29, 1980

Filed:

Jun 8, 1979

Appl. No.:

6/045671

Inventors:

Saul C. Cherkofsky - Wilmington DE
Thomas R. Sharpe - Fort Salonga NY

Assignee:

E. I. Du Pont de Nemours and Company - Wilmington DE

International Classification:

A61K 31415
C07D23528

US Classification:

424273B

Abstract:

Certain 2-substituted-1H-phenanthro[9,10-d]-imidazoles such as 2-[(1,1,2,2-tetrafluoroethyl)-sulfonyl]-1H-phenanthro[9,10-d]imidazole, are useful as antiinflammatory agents.

US Patent:

40642607, Dec 20, 1977

Filed:

Jul 29, 1976

Appl. No.:

5/709819

Inventors:

Saul Carl Cherkofsky - Wilmington DE
Thomas Ray Sharpe - Wilmington DE

Assignee:

E. I. Du Pont de Nemours and Company - Wilmington DE

International Classification:

C07D51304

US Classification:

424270

Abstract:

Diarylimidazothiazoles, such as 2,3-dihydro-5,6-bis(p-methoxyphenyl)imidazo[2,1-b]thiazole, useful as antiinflammatories.

US Patent:

58224130, Oct 13, 1998

Filed:

May 2, 1996

Appl. No.:

8/641860

Inventors:

Thomas A. Dunn - Edison NJ
Howard J. Geiger - Colonia NJ
Mark C. Pollman - Old Bridge NJ
Thomas C. Sharpe - Conyers GA

Assignee:

AT&T Corp - Middletown NJ

International Classification:

H04M 1500

US Classification:

379114

Abstract:

A system for preventing fraudulent calling activity in a telecommunications network when an Automatic Number Identification failure (ANIF) occurs at a switch attempting to process a call within the network. When an ANIF occurs, an operator obtains information equivalent to an Automatic Number Identification (ANI) from the calling party and the system determines whether the call is of a type that would not have been restricted had the ANIF not occurred. If the call would not otherwise have been restricted had the ANIF not occurred, the system automatically assigns a blanket billing restriction to the call which only allows specific call types (such as what are deemed the safer alternate billing methods of collect or credit card) and blocks other restricted call types.